ALGN vs GMED vs PODD
161 measures in 16 categories, one definition each, computed from filings and market data.
ALGN63.7
Align Technology, Inc.
Healthcare · Medical - Devices
$147.31 −1.36%$10.5B mkt cap
Score DNA
Price, rebased to 100 three years ago
ALGN GMED PODD · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 2 |
| Insider $ bought, 180d | — | — | $0.56M |
| Congress purchases, 180d | 0 | 3 | 3 |
| Last Congress purchase | — | 2026-09-03 | 2026-09-11 |
| 13F net change in holders | −13 | −5 | −56 |
| ETFs adding shares, 30d | 516 | 296 | 548 |
| ETFs trimming, 30d | 429 | 225 | 470 |
| Net ETF funds, 30d | +87 | +71 | +78 |
Valuation
16 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| P/E (TTM) | 25.3x
48th
|
19.2x
22nd
|
26.1x
52nd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 2.09
67th
|
0.78
33rd
|
0.32
13th
|
| Price / sales | 2.5x
38th
|
3.3x
50th
|
3.2x
47th
|
| Price / book | 2.5x
38th
|
2.2x
25th
|
6.9x
75th
|
| Price / tangible book | 3.3x
24th
|
4.1x
39th
|
8.4x
59th
|
| Price / free cash flow | 13.8x
19th
|
13.7x
17th
|
32.8x
67th
|
| Price / operating cash flow | 13.8x
23rd
|
11.3x
16th
|
19.1x
44th
|
| Enterprise value | $9.5B
75th
|
$9.8B
78th
|
$10.2B
83rd
|
| EV / sales | 2.3x
27th
|
3.1x
45th
|
3.3x
47th
|
| EV / EBITDA | 13.1x
37th
|
10.4x
18th
|
15.4x
45th
|
| EV / EBIT | 16.7x
24th
|
14.8x
15th
|
18.3x
30th
|
| EV / free cash flow | 12.5x
8th
|
13.1x
11th
|
34.2x
58th
|
| Earnings yield | 4.0%
78th
|
5.2%
90th
|
3.8%
77th
|
| FCF yield | 7.2%
88th
|
7.3%
90th
|
3.0%
60th
|
| Operating cash flow yield | 7.2%
83rd
|
8.8%
88th
|
5.2%
68th
|
| Graham number (per share) | $87.61
85th
|
$54.85
67th
|
$49.93
59th
|
Profitability (TTM)
12 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Gross margin | 66.5%
55th
|
68.5%
65th
|
71.1%
72nd
|
| EBITDA margin | 17.6%
70th
|
30.1%
93rd
|
21.7%
78th
|
| Operating margin | 13.3%
73rd
|
20.8%
90th
|
16.9%
82nd
|
| EBIT margin | 13.7%
73rd
|
21.1%
90th
|
18.3%
83rd
|
| Net margin | 10.0%
75th
|
17.0%
92nd
|
12.3%
82nd
|
| NOPAT margin | 9.7%
65th
|
16.7%
87th
|
12.8%
77th
|
| FCF margin | 18.3%
85th
|
23.9%
97th
|
9.8%
63rd
|
| Operating cash flow margin | 18.3%
72nd
|
28.9%
97th
|
16.7%
65th
|
| R&D / revenue | 9.1%
44th
|
5.9%
27th
|
11.3%
63rd
|
| SG&A / revenue | 43.2%
47th
|
43.1%
45th
|
42.9%
43rd
|
| Stock comp / revenue | 4.5%
53rd
|
1.6%
32nd
|
2.6%
43rd
|
| Effective tax rate | 27.3%
86th
|
19.5%
16th
|
24.1%
83rd
|
Returns on capital
11 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| ROE (on average equity) | 10.2%
68th
|
11.8%
76th
|
26.0%
95th
|
| ROA | 6.5%
73rd
|
10.2%
87th
|
11.3%
93rd
|
| ROIC | 12.3%
76th
|
12.3%
75th
|
21.3%
93rd
|
| ROCE | 12.6%
83rd
|
13.3%
88th
|
23.1%
95th
|
| Return on tangible assets | 9.0%
80th
|
12.7%
90th
|
16.8%
97th
|
| Cash ROIC (OCF / invested capital) | 23.2%
83rd
|
21.2%
80th
|
27.8%
90th
|
| Gross profitability (GP / assets) | 42.9%
60th
|
39.3%
57th
|
68.6%
90th
|
| ROIC, 3-yr average | 11.7%
84th
|
6.9%
67th
|
15.5%
90th
|
| ROIC, 5-yr average | 15.9%
86th
|
10.3%
73rd
|
12.5%
80th
|
| ROE, 5-yr average | 11.7%
75th
|
8.0%
69th
|
20.3%
88th
|
| Incremental ROIC | 26.2%
51st
|
51.5%
65th
|
-41.6%
24th
|
Growth
17 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.4%
29th
|
19.7%
73rd
|
29.4%
86th
|
| Revenue growth (QoQ) | 1.5%
15th
|
3.9%
25th
|
5.3%
35th
|
| Revenue CAGR, 3 yr | 3.5%
17th
|
42.1%
92nd
|
27.7%
89th
|
| Revenue CAGR, 5 yr | 3.6%
17th
|
27.7%
88th
|
25.1%
83rd
|
| Gross profit CAGR, 3 yr | 1.8%
15th
|
38.4%
92nd
|
33.6%
90th
|
| Operating income CAGR, 3 yr | -0.6%
20th
|
40.3%
80th
|
82.3%
96th
|
| Net income growth (TTM YoY) | -5.5%
38th
|
50.1%
71st
|
59.0%
79th
|
| Net income CAGR, 3 yr | 9.6%
40th
|
37.9%
75th
|
81.4%
95th
|
| EPS growth (TTM YoY) | -4.2%
38th
|
48.3%
71st
|
61.8%
75th
|
| EPS CAGR, 3 yr | 12.1%
40th
|
24.5%
70th
|
82.0%
95th
|
| EPS CAGR, 5 yr | -8.0%
10th
|
16.9%
75th
|
— |
| FCF growth (TTM YoY) | 11.4%
43rd
|
43.7%
70th
|
-23.2%
17th
|
| FCF CAGR, 3 yr | 7.3%
15th
|
83.7%
88th
|
— |
| Operating cash flow CAGR, 3 yr | -4.3%
13th
|
70.0%
87th
|
49.9%
74th
|
| Book value CAGR, 3 yr | 7.6%
55th
|
20.9%
88th
|
37.4%
96th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 10.2%
44th
|
11.8%
59th
|
26.0%
89th
|
Margin history & stability
7 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Gross margin, 3-yr average | 68.7%
66th
|
63.7%
47th
|
70.3%
72nd
|
| Operating margin, 3-yr average | 14.9%
77th
|
11.5%
70th
|
16.2%
85th
|
| Net margin, 3-yr average | 10.8%
75th
|
10.8%
77th
|
14.5%
91st
|
| FCF margin, 3-yr average | 15.2%
83rd
|
17.0%
92nd
|
12.5%
77th
|
| Revenue stability (0-1) | 0.98
81st
|
0.90
51st
|
0.95
60th
|
| Earnings stability (0-1) | 0.47
66th
|
0.45
60th
|
0.75
83rd
|
| Margin stability (0-1) | 0.96
58th
|
0.90
15th
|
0.95
38th
|
Liquidity (latest quarter)
7 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Cash & short-term investments | $1.1B
87th
|
$595.1M
82nd
|
$534.9M
77th
|
| Net cash (− = net debt) | $981.7M
98th
|
$483.9M
93rd
|
−$413.5M
32nd
|
| Working capital | $754.5M
73rd
|
$1.7B
87th
|
$1.1B
80th
|
| Current ratio | 1.40
10th
|
4.62
70th
|
2.48
37th
|
| Quick ratio | 1.28
25th
|
2.93
63rd
|
1.83
40th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.58
33rd
|
1.24
55th
|
0.72
38th
|
| Defensive interval (days) | 373 days
67th
|
324 days
50th
|
248 days
30th
|
Leverage & solvency (latest quarter)
13 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Total debt | $120.8M
40th
|
$111.2M
38th
|
$948.4M
70th
|
| Debt / equity | 0.03
11th
|
0.02
7th
|
0.67
60th
|
| Net debt / equity | −0.23
35th
|
−0.10
42nd
|
0.29
53rd
|
| Debt / assets | 1.9%
7th
|
2.0%
8th
|
30.0%
55th
|
| Debt / capital | 2.8%
11th
|
2.3%
7th
|
40.0%
60th
|
| Debt / EBITDA | 0.17
8th
|
0.12
5th
|
1.43
37th
|
| Net debt / EBITDA | −1.35
16th
|
−0.51
24th
|
0.62
34th
|
| Interest coverage (EBIT / interest) | 363.7x
96th
|
— | 8.8x
79th
|
| Cash interest coverage | 483.2x
96th
|
— | 8.1x
75th
|
| Debt payback (years of OCF) | 0.2 yrs
9th
|
0.1 yrs
5th
|
1.9 yrs
28th
|
| Liabilities / assets | 34.0%
37th
|
13.1%
10th
|
55.1%
63rd
|
| IS credit model rating | AAA | AA+ | AA |
| Implied credit spread (bps) | 50
0th
|
65
8th
|
80
17th
|
Efficiency
11 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Asset turnover | 0.66
55th
|
0.60
50th
|
0.92
82nd
|
| Fixed asset turnover | 3.72
26th
|
5.31
60th
|
3.56
21st
|
| Inventory turnover | 6.1
95th
|
1.2
16th
|
1.9
60th
|
| Receivables turnover | 3.7
5th
|
4.8
17th
|
5.9
38th
|
| Days sales outstanding | 100 days
95th
|
76 days
83rd
|
62 days
62nd
|
| Days inventory outstanding | 60 days
5th
|
292 days
84th
|
193 days
40th
|
| Days payables outstanding | 29 days
12th
|
36 days
22nd
|
45 days
37th
|
| Cash conversion cycle (days) | 130 days
28th
|
332 days
92nd
|
209 days
47th
|
| Capex / revenue | 0.0%
0th
|
5.1%
72nd
|
7.0%
91st
|
| Capex / depreciation | 0.00
0th
|
0.57
41st
|
2.02
90th
|
| Operating expense ratio | 53.5%
36th
|
46.3%
22nd
|
54.0%
37th
|
Cash flow & earnings quality
7 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Operating cash flow / net income | 1.83
74th
|
1.70
52nd
|
1.36
37th
|
| FCF / net income | 1.83
85th
|
1.40
56th
|
0.79
15th
|
| FCF / operating cash flow | 100.0%
100th
|
82.4%
71st
|
58.4%
40th
|
| Capex / operating cash flow | 0.0%
0th
|
17.6%
29th
|
41.6%
60th
|
| Accruals ratio | -5.4%
48th
|
-7.2%
35th
|
-4.1%
65th
|
| Sloan accruals ratio | 2.3%
72nd
|
2.9%
75th
|
-7.5%
27th
|
| Earnings quality score (0-1) | 0.75
4th
|
0.75
4th
|
1.00
48th
|
Scores & forensic checks
15 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| IS score | 64
82nd
|
82
100th
|
71
90th
|
| IS profitability | 49
72nd
|
69
92nd
|
71
93rd
|
| IS growth | 38
20th
|
72
80th
|
78
86th
|
| IS value | 41
57th
|
56
82nd
|
43
63rd
|
| IS momentum | 69
52nd
|
97
98th
|
100
100th
|
| IS risk (safety) | 100
62nd
|
100
62nd
|
100
62nd
|
| IS quality | 80
80th
|
88
97th
|
86
93rd
|
| IS balance sheet | 89
83rd
|
86
82nd
|
82
77th
|
| IS earnings quality | 64
65th
|
62
60th
|
73
73rd
|
| IS cash flow | 82
92nd
|
90
98th
|
47
60th
|
| Piotroski F-score (0-9) | 7
70th
|
8
83rd
|
9
95th
|
| Altman Z-score | 5.0
65th
|
10.8
83rd
|
5.8
68th
|
| Beneish M-score | −2.65
54th
|
−2.69
45th
|
−2.45
79th
|
| Ohlson O-score | −9.34
18th
|
−12.74
3rd
|
−8.31
37th
|
| IS credit score | 96
95th
|
93
88th
|
87
80th
|
Size (TTM)
8 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| Market cap | $10.5B
83rd
|
$10.3B
82nd
|
$9.8B
80th
|
| Revenue | $4.1B
85th
|
$3.1B
78th
|
$3.1B
77th
|
| EBITDA | $726.6M
80th
|
$945.8M
82nd
|
$663.6M
78th
|
| Net income | $413.6M
83rd
|
$535.5M
85th
|
$375.3M
82nd
|
| Free cash flow | $755.7M
85th
|
$750.6M
83rd
|
$298.3M
78th
|
| Total assets | $6.4B
82nd
|
$5.5B
77th
|
$3.2B
67th
|
| Shareholders' equity | $4.2B
82nd
|
$4.8B
83rd
|
$1.4B
68th
|
| Employees | 20,435
92nd
|
6,000
72nd
|
5,400
70th
|
Price performance
9 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| 1 day | −1.4% | −2.7% | +1.7% |
| 1 week | +3.2% | +2.7% | +4.3% |
| 1 month | −1.6% | +3.4% | −0.3% |
| 3 months | −15.8% | +0.9% | −15.7% |
| 6 months | −22.5% | −19.5% | −30.7% |
| Year to date | −5.6% | −12.2% | −50.1% |
| 1 year | +14.7% | +31.5% | −54.8% |
| 3 years, cumulative | −46.9% | +44.6% | +5.7% |
| 5 years, cumulative | −77.1% | +0.8% | −51.5% |
Technicals
4 measures| Measure | ALGN | GMED | PODD |
|---|---|---|---|
| RSI 14 | 49.8 | 51.4 | 55.6 |
| From 52-week high | −26.5% | −24.4% | −60.2% |
| From 52-week low | +14.5% | +31.5% | +11.6% |
| Beta | 1.67 | 0.96 | 1.10 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17